Tags

Type your tag names separated by a space and hit enter

Safety and tolerability of COMT inhibitors.
Neurology. 2004 Jan 13; 62(1 Suppl 1):S39-46.Neur

Abstract

Combining levodopa with the catechol-O-methyltransferase (COMT) inhibitor entacapone has been shown to be an effective strategy in the management of Parkinson's disease (PD) patients experiencing motor fluctuations. Safety and tolerability information has come from postmarketing surveillance studies as well as several randomized, placebo-controlled trials with long-term open-label extension phases specifically investigating the safety and tolerability of levodopa plus entacapone. Results show the most common dopaminergic side effects to be dyskinesia and nausea, which result from the increased bioavailability of levodopa and can be readily managed. Non-dopaminergic side effects include diarrhea and harmless urine discoloration. There is no convincing evidence of hepatic injury with entacapone use, and therefore monitoring of liver enzymes is unnecessary. With over 300,000 patient-years of exposure, levodopa combined with entacapone can be considered safe and well tolerated.

Authors+Show Affiliations

MRC Clinical Sciences Centre, Faculty of Medicine, Imperial College London, Hammersmith Hospital, United Kingdom.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

14718679

Citation

Brooks, David J.. "Safety and Tolerability of COMT Inhibitors." Neurology, vol. 62, no. 1 Suppl 1, 2004, pp. S39-46.
Brooks DJ. Safety and tolerability of COMT inhibitors. Neurology. 2004;62(1 Suppl 1):S39-46.
Brooks, D. J. (2004). Safety and tolerability of COMT inhibitors. Neurology, 62(1 Suppl 1), S39-46.
Brooks DJ. Safety and Tolerability of COMT Inhibitors. Neurology. 2004 Jan 13;62(1 Suppl 1):S39-46. PubMed PMID: 14718679.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Safety and tolerability of COMT inhibitors. A1 - Brooks,David J, PY - 2004/1/14/pubmed PY - 2004/2/5/medline PY - 2004/1/14/entrez SP - S39 EP - 46 JF - Neurology JO - Neurology VL - 62 IS - 1 Suppl 1 N2 - Combining levodopa with the catechol-O-methyltransferase (COMT) inhibitor entacapone has been shown to be an effective strategy in the management of Parkinson's disease (PD) patients experiencing motor fluctuations. Safety and tolerability information has come from postmarketing surveillance studies as well as several randomized, placebo-controlled trials with long-term open-label extension phases specifically investigating the safety and tolerability of levodopa plus entacapone. Results show the most common dopaminergic side effects to be dyskinesia and nausea, which result from the increased bioavailability of levodopa and can be readily managed. Non-dopaminergic side effects include diarrhea and harmless urine discoloration. There is no convincing evidence of hepatic injury with entacapone use, and therefore monitoring of liver enzymes is unnecessary. With over 300,000 patient-years of exposure, levodopa combined with entacapone can be considered safe and well tolerated. SN - 1526-632X UR - https://www.unboundmedicine.com/medline/citation/14718679/Safety_and_tolerability_of_COMT_inhibitors_ L2 - http://www.neurology.org/cgi/pmidlookup?view=long&pmid=14718679 DB - PRIME DP - Unbound Medicine ER -